BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy

BRAF and MEK inhibitors have improved clinical outcomes in advanced, BRAF(V600)-mutated melanomas. Acquired resistance occurs in most patients, with numerous and diverse drivers. We obtained pre-treatment and progression biopsies from a patient who progressed on dabrafenib and trametinib. In additio...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Pigment Cell Melanoma Res
Main Authors: Johnson, Douglas B., Childress, Merrida A., Chalmers, Zachary R., Frampton, Garrett M., Ali, Siraj M., Rubinstein, Samuel M., Fabrizio, David, Ross, Jeffrey S., Balasubramanian, Sohail, Miller, Vincent A., Stephens, Philip J., Sosman, Jeffrey A., Lovly, Christine M.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889338/
https://ncbi.nlm.nih.gov/pubmed/29171936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12674
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki